• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Social Work Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Pregnancy and Postpartum Course
    • Blog
    • Psychiatry News Videos
    • Medication Guide Videos
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • FAQs
  • Pregnancy and Postpartum Course
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Access Purchased Content
Home » Note From the Editor-in-Chief
Note From the Editor-in-Chief

Note From the Editor-in-Chief

July 31, 2025
Noah Capurso, MD, MHS
From The Carlat Addiction Treatment Report
Issue Links: Editorial Information | PDF of Issue

Noah Capurso, MD, MHS. Assistant Medical Director, Addiction Services Division, Connecticut Valley Hospital; Associate Clinical Professor of Psychiatry, Yale University; Editor-in-Chief, The Carlat Addiction Treatment Report.

Dr. Capurso has no financial relationships with companies related to this material.

Getting your Trinity Audio player ready...

In May, the CDC reported a remarkable improvement in drug overdose deaths across the United States. The number fell from 110,037 in 2023 to 80,391 in 2024—a nearly 27% reduction in a single year and the largest annual decrease since the overdose epidemic began over three decades ago. Nearly all regions saw improvements, with some of the hardest-hit areas—such as West Virginia, Ohio, and Washington, DC—experiencing declines of 35% or more. Researchers are still working to understand the causes of this progress, but likely contributors include expanded access to buprenorphine and methadone, widespread naloxone distribution, including over-the-counter availability, and growing adoption of harm reduction strategies. A shrinking supply of fentanyl and a shift toward lower potency in the illicit drug market may also have played a role. While this is encouraging news, overdose death rates remain high and are still above pre-pandemic levels. So we need to keep the momentum going: Continue to deliver evidence-based addiction care, embrace harm reduction, and ensure every patient has access to naloxone.

—Noah Capurso, MD, MHS

noah.capurso@yale.edu

Addiction Treatment
KEYWORDS overdose deaths overdose epidemic public health
    Ncapurso
    Noah Capurso, MD, MHS

    Brixadi: A New Long-Acting Buprenorphine Option for Opioid Use Disorder

    More from this author
    www.thecarlatreport.com
    Issue Date: July 1, 2025
    SUBSCRIBE NOW
    Table Of Contents
    Learning Objectives, Psychotherapy For Addiction, CATR, July/August/September 2025
    Note From the Editor-in-Chief
    Substance Use Disorder Treatment: Medication or Psychotherapy?
    Motivational Interviewing
    Supporting Sobriety With 12-Step Facilitation
    Brixadi: A New Long-Acting Buprenorphine Option for Opioid Use Disorder
    Buprenorphine Induction Using Long-Acting Injection
    Starting Long-Acting Buprenorphine During Medical Hospitalization
    CME Post-Test, Psychotherapy For Addiction, CATR, July/August/September 2025
    DOWNLOAD NOW
    Featured Book
    • OUDFB1e_Cover_Binding.png

      Treating Opioid Use Disorder—A Fact Book (2024)

      All the tools you need to assess and treat patients struggling with opioid use disorder. 
      READ MORE
    Featured Video
    • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
      General Psychiatry

      KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

      Read More
    Featured Podcast
    • shutterstock_2637648401.jpg
      General Psychiatry

      Psychopharm Secrets: Coming Off Meds

      There’s a hidden placebo response to watch for when patients stop meds on their own.
      Listen now
    Recommended
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png

    About

    • About Us
    • CME Center
    • FAQ
    • Contact Us

    Shop Online

    • Newsletters
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN Self-Assessment Courses

    Newsletters

    • The Carlat Psychiatry Report
    • The Carlat Child Psychiatry Report
    • The Carlat Addiction Treatment Report
    • The Carlat Hospital Psychiatry Report
    • The Carlat Geriatric Psychiatry Report
    • The Carlat Psychotherapy Report

    Contact

    carlat@thecarlatreport.com

    866-348-9279

    PO Box 626, Newburyport MA 01950

    Follow Us

    Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

    © 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.